Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma Plc (RPRX) drives biopharmaceutical innovation by funding therapies through strategic royalty acquisitions. This dedicated news hub provides investors with essential updates on the company's financial developments and industry impact.
Access real-time announcements including quarterly earnings, royalty agreement expansions, and regulatory milestones. Our curated feed helps stakeholders track RPRX's role in advancing treatments across oncology, immunology, and rare diseases.
Discover how Royalty Pharma's unique business model supports drug development while maintaining revenue stability. The page features verified updates on portfolio additions, strategic collaborations, and market analyses relevant to RPRX's position in healthcare finance.
Bookmark this page for streamlined access to Royalty Pharma's official communications and third-party analyses. Check regularly for insights into how the company continues shaping biopharma funding through calculated royalty investments.
Royalty Pharma plc (Nasdaq: RPRX) has authorized a share repurchase program of up to $1.0 billion for its Class A ordinary shares, with shareholder approval valid through June 2027. CEO Pablo Legorreta also plans to purchase an additional $50 million of these shares. This initiative reflects confidence in Royalty Pharma's growth potential and solid balance sheet, boosted by recent Biohaven-related payments. The company targets capital deployment of $10 to $12 billion over the next five years to invest in life sciences innovation while creating shareholder value.
Royalty Pharma has acquired an interest in PureTech’s royalty from Karuna Therapeutics for its therapy, KarXT, valued at up to
Royalty Pharma (RPRX) announced a significant adjustment to its 2023 financial guidance, now expecting Adjusted Cash Receipts between $2,850 million and $2,950 million, up from previous estimates of $2,375 million to $2,475 million. This change follows a $475 million milestone payment from Pfizer after the FDA approved Zavzpret, a new migraine treatment. Royalty Pharma will collect royalties from both Zavzpret and Nurtec ODT sales. The guidance assumes no unforeseen adverse events and may be adjusted for new royalty transactions.
Royalty Pharma (Nasdaq: RPRX) has appointed Ashwin Pai, M.D., as Executive Vice President, Investments effective April 2023. He joins from Morgan Stanley, bringing nearly two decades of experience in biotechnology investment banking, having led major mergers and acquisitions. Ashwin's role will focus on sourcing and executing transactions, enhancing Royalty Pharma’s position within the life sciences sector, particularly on the West Coast. The firm, established in 1996, is a leading funder of biopharmaceutical innovation, holding royalties on over 35 commercial products, including therapies from Vertex and Biogen.
Royalty Pharma (Nasdaq: RPRX) reported Q4 and full year 2022 results showcasing strong financial performance. Net cash from operating activities reached $570 million, reflecting a 16% increase for the quarter and 6% for the year. Adjusted Cash Receipts surged 96% to $1,064 million in Q4 and 31% to $2,789 million for the year, driven by a $458 million payment from Pfizer’s Biohaven acquisition. For 2023, the company expects Adjusted Cash Receipts between $2,375 million and $2,475 million, excluding potential milestone payments. Royalty acquisitions in 2022 totaled up to $3.5 billion, bolstering its growth outlook.
Royalty Pharma plc (Nasdaq: RPRX) announced its participation in two upcoming investor conferences. The events include the SVB Securities Global Biopharma Conference on February 16 at 10:40 a.m. ET and the Cowen 43rd Annual Health Care Conference on March 7 at 11:10 a.m. ET. The webcasts for these conferences will be available on Royalty Pharma’s Events page and will remain accessible for at least thirty days after the events. Royalty Pharma, founded in 1996, is a leader in biopharmaceutical royalty acquisition and funding innovation in the industry, boasting a portfolio exceeding 35 commercial products. For more details, visit their official website.
Royalty Pharma (RPRX) announced it will report its Q4 and full year 2022 financial results on February 15, 2023, before the U.S. markets open. The company will host a conference call at 8:00 a.m. ET to discuss the results. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation across the industry, supporting numerous therapies through its extensive portfolio of royalties from over 35 commercial products, such as Vertex’s Trikafta and Biogen’s Tysabri. For further details, visit their Investors page.
Royalty Pharma (RPRX) has reported a strong operational performance for 2022, forecasting Net cash provided by operating activities of approximately $2.14 billion to $2.15 billion and Adjusted Cash Receipts of $2.785 billion to $2.79 billion, marking a 31% year-over-year growth. The company has achieved significant capital deployment, announcing $10 billion in transactions since 2020, projected to contribute $1 billion to future receipts. Management emphasizes resilience amid revenue declines in key areas, positioning for innovation and growth.
Royalty Pharma (RPRX) announced its acquisition of an interest in SPINRAZA® and pelacarsen royalties from Ionis Pharmaceuticals. The deal totals up to $1.125 billion, including a $500 million upfront payment and up to $625 million in milestone payments. Ionis retains a majority of the royalties and milestone payments for pelacarsen, expected to advance its late-stage programs and innovative pipeline. This partnership aims to enhance the commercial readiness of Ionis’s therapies targeting spinal muscular atrophy and cardiovascular diseases.
Ionis Pharmaceuticals has announced a significant royalty agreement with Royalty Pharma, involving an upfront payment of $500 million and potential milestones of up to $625 million. This deal allows Royalty Pharma to acquire an interest in Ionis' royalties from SPINRAZA and pelacarsen, while Ionis retains the majority of royalties and milestone payments from Novartis. The investment aims to bolster Ionis' late-stage programs and innovative genetic medicines pipeline, highlighting confidence in the commercial potential of both therapies.
